Genfit S.A. Q1 Results: Revenue Up 154.5% YoY, Cash Reserves Surge to €129.5M.

Genfit S.A. reported Q1 revenue of €2.8M, a 154.5% YoY increase. As of March 31, 2025, the company's cash and cash equivalents totaled €129.5 million, up from €74.0 million as of March 31, 2024, and €81.8 million as of December 31, 2024.

Genfit S.A., a biopharmaceutical company focused on improving the lives of patients with rare and life-threatening liver diseases, has announced its first-quarter 2025 financial results. The company reported a significant increase in revenue and an improvement in its cash position.

Revenue for the first three months of 2025 amounted to €2.8 million, a 154.5% year-over-year (YoY) increase compared to the same period in 2024, when revenue was €1.1 million. This growth can be attributed to royalties from the sales of Iqirvo® (elafibranor) from Ipsen, as the company transitioned from transition services agreements to direct revenue from product sales [1].

As of March 31, 2025, Genfit's cash and cash equivalents totaled €129.5 million, up from €74.0 million as of March 31, 2024, and €81.8 million as of December 31, 2024. The increase in cash and cash equivalents is primarily due to the completion of a non-dilutive royalty financing agreement with HCRx, which triggered a €130.0 million first installment paid to Genfit, offset by the repurchase of 1,882,891 2025 OCEANEs totaling €61.7 million [1].

The company's cash runway has been significantly extended beyond the end of 2027, enabling further development of its pipeline focused on Acute-on-Chronic Liver Failure (ACLF) and support for general corporate purposes. This extension is based on current assumptions and programs, including expectations to receive significant future milestone revenue under the license and collaboration agreement with Ipsen [1].

Genfit's cash position and revenue growth reflect the company's strong financial performance and its ability to secure additional financing. However, investors should remain aware of the risks and uncertainties associated with research and development, regulatory approvals, and market conditions, as highlighted in the company's forward-looking statements [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/1001098413/genfit-reports-first-quarter-2025-financial-information